Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS

Home based Augmented Reality Platform for Efficient Rehabilitation of stroke patients

Project description

Mixed reality innovation helping stroke patients on the road to rehabilitation

Stroke is the most common cause of long-term disability world-wide, and innovations are key to improving access to effective screening, diagnostics and treatment, and to following the EU's Action Plan for Stroke. There are millions of stroke victims each year that need effective individualised treatment which can be achieved by using the innovative products from the Swedish company, BRAIN STIMULATION AB. RehAtt® is a method based on the latest neuroscience technology, now available using smart glasses. It can be used at home after discharge to improve function, independence and quality of life, through fun, motivating and stimulating 3D games in Mixed Reality. The EU-funded project HARPER will help pave the way for the innovative products' entry into the global market.

Objective

Brain Stimulation AB is a Swedish SME started in 2011 with the aim of exploiting brain plasticity results from research within
a new concept of rehabilitation and diagnosis of cognitive impairments of attention in stroke patients (the Neglect
Syndrome). We address the global challenge of rehabilitating patients with cognitive and upper limb problems from Stroke,
Dementia, Traumatic Brain Injuries, Parkinson and other degenerative brain diseases. Cognitive impairments as in the
Neglect Syndrome is not discovered nor treated in suitable time and the normal hospital stay is too short to rehabilitate the
patients properly. Our innovation meets the need of early detection and diagnosis as well as efficient rehabilitation of
patients in clinics and that can continue in patients’ home environment. If the Neglect Syndrome is discovered and treated
faster and better than today, the wellbeing of patients will increase. The burden and the costs for their care will be
significantly reduced. Around 30% of the 16 Million new stroke patients worldwide per year suffer from the Neglect
Syndrome i.e. there are 5-6 million new patients per year. Our addressable market exceeds 6 Million patients per year as our
ambition is to reach not just the stroke patients with Neglect Syndrome but also Dementia, Traumatic Brain Injuries,
Parkinson and other degenerative brain diseases. The innovation project will lead to a generation of €10,3 Million in turnover
and creating 40 new job positions in a five-year perspective after market-launch as well as creating IP rights from the
outcome of the Project. The goal is to develop, verify and bring our innovation towards global market launch. We will go
from TRL 6 towards TRL 9 during the full innovation project life cycle. There will be sustainable effects in economic, ecologic
and social terms for effective cognitive rehabilitation performed in people’s homes, with therapist support through e-health
solutions, when needed.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

BRAIN STIMULATION AB
Net EU contribution
€ 50 000,00
Address
LOVOUDDEN 619
913 33 HOLMSUND
Sweden

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Norra Sverige Övre Norrland Västerbottens län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00